生物活性：Sorafenib-d3 (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively[1].
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物开发过程中定量的示踪剂。氘代因其可能影响药物的药代动力学和代谢特征而受到关注[1]。氘代化合物的潜在优势： (1) 延长半衰期体内。氘代化合物可能能够延长化合物的药代动力学特征，即延长体内半衰期。这可以提高化合物的安全性、功效和耐受性，并增加给药的便利性。 (2) 提高口服生物利用度。氘化化合物可以降低肠壁和肝脏中不需要的代谢 (首过代谢) 的程度，使更大比例的未代谢药物到达其作用靶点。高生物利用度决定了它在低剂量下的活性和更好的耐受性。 (3) 改善代谢特性。氘代化合物可以减少有毒或反应性代谢物的形成并改善药物代谢。 (四) 提高用药安全性。氘代化合物可以减少或消除药物化合物的不良副作用并且是安全的。 (5) 保持疗效。在先前的研究中，预计氘代化合物将保留与氢类似物相似的生化效力和选择性。
QY千亿国际 has not independently confirmed the accuracy of these methods. They are for reference only.
Sorafenib-d3 相关抗体:
ERK1/2 Antibody
E-Cadherin Antibody (YA470)
Fatty Acid Synthase Antibody (YA766)
DYKDDDDK Tag (FLAG) Antibody
GAPDH Antibody
GFP Antibody
p53 Antibody (YA250)
RUNX2 Antibody
Ferritin Heavy Chain Antibody
COX2 Antibody
Ctip2 Antibody
Cyclin D1 Antibody (YA485)
Cytochrome C Antibody
BRAF Antibody
c-Myc Antibody
Cyclin E1 Antibody
Phospho-BRAF (Thr401) Antibody
AIF Antibody (YA636)
ALIX Antibody
A-RAF Antibody
B-Raf Antibody
CNPase Antibody
Cortactin Antibody
COX IV Antibody
COX2/Cyclooxygenase 2 Antibody
Cyclin A2 Antibody
Cyclin B1 Antibody (YA486)
DR5 Antibody
Drosha Antibody
E-Cadherin Antibody (YA778)
Clinical Trial
NCT NumberSponsorConditionStart DatePhaseNCT04418401Zhejiang UniversityHepatocellular CarcinomaJune 11, 2020Phase 1NCT05713994Wan-Guang Zhang|Chinese Cooperative Group of Liver Cancer (CCGLC)|Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province|Haplox Biotechnology Co., Ltd.|Geneplus-Beijing Co. Ltd.|The Second Affiliated Hospital of Fujian Medical University|Tongji HospitalHepatocellular Carcinoma Non-resectableMay 1, 2020NCT04962958Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Meng Chao Hepatobiliary Hospital of Fujian Medical University|Huashan Hospital|The Second Affiliated Hospital of Harbin Medical UniversityCarcinoma|Carcinoma, Hepatocellular|Liver Neoplasms|Digestive System Neoplasms|Antineoplastic Agents|Donafenib|Fluorouracil|Oxaliplatin|AntimetabolitesJuly 1, 2023Phase 2 NCT05576909Beijing Tsinghua Chang Gung Hospital|Suzhou Zelgen Biopharmaceuticals Co.,LtdHepatocellular CarcinomaMarch 30, 2023Phase 2NCT04402723Suzhou Zelgen Biopharmaceuticals Co.,LtdAcute Myeloid Leukemia (AML)November 6, 2018Phase 1NCT05166772Tianjin Medical University Cancer Institute and HospitalHepatocellular CarcinomaDecember 2021Phase 2NCT05171166Peking UniversityHepatocellular CarcinomaDecember 24, 2021Phase 2|Phase 3NCT02229071Suzhou Zelgen Biopharmaceuticals Co.,Ltd|Tigermed Consulting Co., LtdHCCApril 2014Phase 1|Phase 2NCT02870582Suzhou Zelgen Biopharmaceuticals Co.,LtdMetastatic Colorectal CancerDecember 28, 2016Phase 3NCT04059874First Affiliated Hospital of Zhejiang UniversityNon-small Cell Lung CancerJuly 31, 2019Phase 1NCT02698111Suzhou Zelgen Biopharmaceuticals Co.,LtdNasopharyngeal CarcinomaFebruary 8, 2017Phase 1|Phase 2NCT03602495Suzhou Zelgen Biopharmaceuticals Co.,LtdDifferentiated Thyroid CancerAugust 29, 2018Phase 3NCT05138159Fudan UniversityMetastatic Pancreatic CancerDecember 1, 2021Phase 2NCT04503902Suzhou Zelgen Biopharmaceuticals Co.,LtdAdvanced Hepatocellular CarcinomaOctober 15, 2020Phase 1|Phase 2NCT02870569Suzhou Zelgen Biopharmaceuticals Co.,LtdDifferentiated Thyroid CancerSeptember 2016Phase 2NCT05022628Anhui Provincial HospitalHCC|Chemotherapy EffectSeptember 30, 2021Phase 4NCT05310331Lei Li|Peking Union Medical College HospitalTargeted Therapy|Chemotherapy|Recurrent Cervical Carcinoma|Metastatic Cervical Carcinoma|Persistent Advanced Cervical Carcinoma|Survival Outcomes|Adverse EffectMarch 27, 2022Phase 2NCT05493332Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHepatocellular CarcinomaSeptember 2022Phase 2NCT05717738Tongji Hospital|Chinese Cooperative Group of Liver Cancer (CCGLC)|Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province|The Second Affiliated Hospital of Fujian Medical University|Geneplus-Beijing Co. Ltd.|Haplox Biotechnology Co., Ltd.Hepatocellular Carcinoma Non-resectableJanuary 20, 2022NCT02489214Suzhou Zelgen Biopharmaceuticals Co.,LtdGastric CancerMay 16, 2016Phase 1|Phase 2NCT02489201Suzhou Zelgen Biopharmaceuticals Co.,LtdOesophageal CancerJuly 21, 2015Phase 1|Phase 2NCT05205629Shanghai Zhongshan HospitalHepatocellular Carcinoma|DonafenibJanuary 30, 2022NCT05161143Peking Union Medical College Hospital|Suzhou Zelgen Biopharmaceuticals Co.,LtdHepatocellular CarcinomaDecember 2021Phase 2NCT05350943Lu Wang, MD, PhD|Fudan UniversityBiliary Tract AdenocarcinomaMarch 1, 2022Phase 2NCT02645981Suzhou Zelgen Biopharmaceuticals Co.,Ltd|Tigermed Consulting Co., LtdHCCMarch 2016Phase 2|Phase 3NCT05545124Henan Cancer HospitalHepatocellular CarcinomaNovember 2022Phase 2NCT04612712Suzhou Zelgen Biopharmaceuticals Co.,Ltd|Jiangsu Alphamab Biopharmaceuticals Co., LtdAdvanced Gastrointestinal TumorsJanuary 19, 2021Phase 1|Phase 2NCT05507632Nanfang Hospital, Southern Medical UniversityUnresectable Hepatocellular CarcinomaAugust 15, 2022Phase 2NCT04979663Fudan UniversityBiliary Tract CarcinomaDecember 1, 2020Phase 1|Phase 2NCT05668884Fudan UniversityBiliary Tract CarcinomaOctober 18, 2022Phase 2NCT05348811Zhongda HospitalCholangiocarcinomaDecember 28, 2022Phase 2NCT04472858Suzhou Zelgen Biopharmaceuticals Co.,Ltd|CStone PharmaceuticalsAdvanced Solid TumorOctober 15, 2020Phase 1NCT04605185Suzhou Zelgen Biopharmaceuticals Co.,LtdUnresectable Hepatocellular CarcinomaJanuary 8, 2021Phase 1
分子量：467.84
Formula：C21H13D3ClF3N4O3
CAS 号：1130115-44-4
非标记 CAS：284461-73-0
性状：固体
颜色：White to off-white
中文名称：索拉非尼 d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Powder：-20°C：3 years，4°C：2 years
In solvent：-80°C：6 months，-20°C：1 month